Mahamaya Lifesciences Limited has announced its financial results for the fiscal year 2025-26 (FY26), reporting a robust 25% year-on-year (YoY) growth in revenue. The company's total revenue for FY26 stood at Rs 32,887.30 lakhs (approximately Rs 328.87 crore), compared to Rs 26,309.84 lakhs in the previous fiscal year.
Strong H2 Performance
In the second half of FY26 (H2 FY26), the company achieved revenue of Rs 16,580.93 lakhs (around Rs 165.81 crore), reflecting consistent growth momentum. The H2 performance contributed significantly to the annual figures, underscoring the company's operational efficiency and market demand for its products.
Growth Drivers
The revenue increase was primarily driven by higher sales volumes and improved product mix across key therapeutic segments. The company's focus on expanding its distribution network and strengthening its presence in existing markets also played a crucial role. Additionally, cost optimization measures helped maintain healthy margins despite rising input costs.
- Revenue Growth: 25% YoY increase to Rs 328.87 crore in FY26.
- H2 Revenue: Rs 165.81 crore, contributing half of the annual total.
- Operational Efficiency: Improved margins through cost control and product mix optimization.
Financial Highlights
Mahamaya Lifesciences has demonstrated resilience in a competitive pharmaceutical landscape. The company's ability to sustain double-digit growth reflects its strategic initiatives and strong execution capabilities. Management remains optimistic about future prospects, citing a robust pipeline and expansion plans.
The company did not provide specific net profit figures in the announcement, but the revenue growth indicates healthy business performance. Mahamaya Lifesciences continues to focus on research and development to introduce new products and enhance its portfolio.
Outlook
Looking ahead, the company aims to maintain growth trajectory through geographic expansion, product diversification, and strategic partnerships. The pharmaceutical sector's steady demand and the company's agile operations are expected to support continued progress.
- Revenue growth of 25% YoY in FY26.
- H2 FY26 revenue of Rs 165.81 crore.
- Focus on operational efficiency and market expansion.
Mahamaya Lifesciences remains committed to delivering value to stakeholders through sustainable growth and innovation.
